p53 Immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma
Authors:
- John R. GoldblumJGJohn R. Goldblum
- Gary W. FalkGFGary W. Falk
- Raymond R. TubbsRTRaymond R. Tubbs
- Thomas J. KirbyTKThomas J. Kirby
- Graham CaseyGCGraham Casey
- 1 December 1994
- journal article
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 108 (6) , 1132-1137
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Potential application of p53 as an intermediate biomarker in Barrett's esophagusThe Annals of Thoracic Surgery, 1994
- p53 Mutations are common in pancreatic cancer and are absent in chronic pancreatitisCancer Letters, 1993
- ras-Induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutationCell, 1992
- Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometryGastroenterology, 1992
- Oncogene activation in esophageal cancerThe Journal of Thoracic and Cardiovascular Surgery, 1991
- Barrett's Esophagus; Development of Dysplasia and AdenocarcinomaGastroenterology, 1989
- Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagusBritish Journal of Surgery, 1988
- Observer variation in the diagnosis of dysplasia in Barrett's esophagusHuman Pathology, 1988
- Adenocarcinoma and Barrett's esophagusGastroenterology, 1984
- Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applicationsHuman Pathology, 1983